Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.
May’s Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter
[table “42” not found /]May’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The top five pharmaceutical companies mentioned by healthcare professionals (HCPs) in the month of May 2021 remained the same as last month. The only difference being that Pfizer displaced AstraZeneca as the most talked about pharmaceutical company for the first time in three months. Johnson & Johnson was positioned in third place, followed by GSK and Merck & Co.
In May 2021, the HCP conversation decreased from the previous month by 32%, making it one of the quieter months of this year. While HCPs continued to discuss efficacy and safety of COVID-19 vaccines, one of the key drivers of conversation was accessibility of treatments and vaccines in different countries.
In one of the most active conversations, 52 HCPs shared a Tweet showing discontent over the Canadian government’s decision to not donate soon-to-expire AstraZeneca vaccines to India. HCPs also shared the news that Chile and Argentina are not providing the Pfizer vaccine since their governments could not reach a deal with the pharmaceutical company; and how in Spain there could be a vaccine supply problem due to the trend in people choosing AstraZeneca over Pfizer for their second doses.
Thousands of Astra-Zeneca doses are about to expire this weekend in Ontario, while thousands of Indians are dying each day, without access to vaccination. 500K more Indians would have been vaccinated had they not sent Canada those doses in our time of need. I am not OK with this.
— Samir Gupta (@SammyG_MD) May 28, 2021
España: AstraZeneca arrasa entre quienes podían elegir segunda dosis de Pfizer, lo que impacta en el plan de vacunación. Si la tendencia se confirma puede acabar generando problemas de abastecimiento. https://t.co/rWXgfwDzYo
— Gorka Orive (@gorka_orive) May 28, 2021
Regarding vaccine efficacy and safety, HCPs shared how medical professionals have been studying the relationship between blood clots and vaccines to understand the “why” of the occurrences that have happened from the AstraZeneca and J&J’s vaccines. Additionally, HCPs shared excitement about the EMA and FDA emergency authorisation for the Pfizer vaccine for adolescents between the ages 12 to 15 since it will help various nations to reach high levels of population immunity.
Se van sumando piezas al puzle de los raros trombos asociados a las vacunas con vectores adenovirales (AstraZeneca/Janssen). Sin embargo, dista de estar resuelto del todo (aunque diversos medios nos hagan pensar lo contrario).https://t.co/7x9Am89uID a través de @eldiarioes
— Esther Samper (@Shora) May 28, 2021
This is big. FDA set to authorize Pfizer for 12-15 year-olds. Soon
About 16 million humans in this age group in US
Getting them vaccinated will help US effort to get high levels of population immunity
I have 2 such humans at home ready to get the shothttps://t.co/aXjYxE8ddL
— Ashish K. Jha, MD, MPH (@ashishkjha) May 3, 2021
The three most shared links by HCPs in May were:
- The FDA press release for the authorisation of the Pfizer COVID-19 vaccine in adolescents.
- A news article from EMA showing the change to recommended storage conditions for the Pfizer COVID-19 vaccine.
- A study report showing the effectiveness of the Pfizer (88%) and AstraZeneca (60%) COVID-19 vaccines against the Delta variant.
Between April and May the volume of HCP COVID-19 conversation in the context of top 50 pharma decreased by over 20,000 posts, making up 68% of the overall HCP conversation in May, down from 77% in April.
Outside of the COVID-19 conversation, influential HCP Eric Feigl-Ding called for more financial equality in accessing insulin in the US, citing the cost to manufacture as well as the 2018 salaries of pharmaceutical company CEOs. The company Bayer was also mentioned by HCPs as finerenone met the primary endpoint in the Phase III FIGARO-DKD trial and other endpoints in the FIDELIO and FIGARO trials.
Bayer’s Finerenone Meets Primary Endpoint (4 point MACE of CV death+MI+stroke+HF hospitalization) in Phase III FIGARO-DKD
In T2DM+CKD patients, finerenone improves renal endpoints (FIDELIO trial) and now also improves CV endpoints (FIGARO) @ChristosArgyrop @AndrewJSauer pic.twitter.com/mOkGrHy4cZ— Carlos G Santos-Gallego, MD (@SantosGallegoMD) May 10, 2021
3) Let this sink in:
In 2018:
J&J CEO made $30M
Pfizer CEO made $28M
Merck CEO made $18M
Eli Lilly CEO made $16M
Gilead CEO made $16MWhile:
📌Americans spent $535B on Rx drugs
📌1/4 of diabetics rationed insulin to survive
📌500K Americans went bankrupt from medical bills. pic.twitter.com/gDefuD5YWH
— Eric Feigl-Ding (@DrEricDing) May 6, 2021
CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
- In May 2021, CREATION Pinpoint® identified 61,281 healthcare professional (HCP) authored tweets from 18,047 individual HCPs mentioning a Top 50 pharmaceutical company (according to revenue).
- Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 pharmaceutical company between May 1st and May 31st 2021.
- Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
- In some cases, a tweet may mention more than one company account (eg. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In May, 1,853 of these posts mentioned Janssen.
